| Identification | Back Directory | [Name]
Lanreotide | [CAS]
108736-35-2 | [Synonyms]
IPSTYL
AUTOGEL
DC-13-116
BIM-23014
bim-23014c
LANREOTIDE
Somatuline
LaroMustine
ANGIOPEPTIN
Lanreotide, Angiopeptin
H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2
B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am
B-NAPHTHYL-D-ALA-CYS-TYR-D-TRP*LYS-VAL-C YS-THR AMID
D-βNal-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2
BETA-(2-NAPHTHYL)-D-ALA-CYS-TYR-D-TRP-LYS-VAL-CYS-THR AMIDE
H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2, (DISULFIDE BOND)
(D-2-NAL5,CYS6,11,TYR7,D-TRP8,VAL10)-SOMATOSTATIN (5-12) AMIDE
3-(2-Naphtyl)-D-Ala-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Thr-NH2
β-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr amide [disulfide bridge: 2-7]
3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2-7)-disulfide
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7) disulfide, TFA salt
DC-13-116, Angiopeptin, (D-2-Nal5,Cys6'11,Tyr7,D-Trp8,Val10)-SoMatostatin (5-12) aMide, BIM-23014, (D-2-Nal5,Cys6·11,Tyr7,D-Trp8,Val10)-SoMatostatin (5-12) aMide | [EINECS(EC#)]
689-178-4 | [Molecular Formula]
C54H69N11O10S2 | [MDL Number]
MFCD03424071 | [MOL File]
108736-35-2.mol | [Molecular Weight]
1096.32 |
| Chemical Properties | Back Directory | [Appearance]
White to off-white lyophilised powder | [Boiling point ]
1508.2±65.0 °C(Predicted) | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [pka]
9.90±0.15(Predicted) | [Sequence]
D-2-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 | [InChIKey]
PUDHBTGHUJUUFI-VHAAONQQNA-N |
| Hazard Information | Back Directory | [Chemical Properties]
White to off-white lyophilised powder | [Description]
Lanreotide is a synthetic octapeptide analogue of somatostatin with enhanced metabolic stability compared with somatostatin. It binds with high affinity to and stimulates the somatostatin receptors SSTR2 and SSTR5, with relatively greater potency at SSTR2 and very low binding to SSTR1, SSTR3 and SSTR4. It is used to treat acromegaly and neuroendocrine tumors.
| [Uses]
Antineoplas tic. | [Clinical Use]
#N/A | [Side effects]
Lanreotide depot was generally well tolerated, as 88% of patients had adverse events, compared with the placebo at 90%. Most adverse events were mild (17%) or moderate (44%) in both lanreotide and placebo groups. The most common adverse event was diarrhea at 26% in the lanreotide group and 9% with placebo. Abdominal pain was recorded in 14% of patients taking lanreotide but only occurred in 2% of patients taking placebo. Cholelithiasis occurred in 10% of patients but only 3% in the placebo group. Hyperglycemia occurred in 5% of lanreotide patients but was not observed in placebo patients.
| [in vivo]
Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. | Animal Model: | Male nude mice, 8 weeks old and 20–25?g in body weight (GH3 tumor-bearing nude mice)[1] | | Dosage: | 2.5, 5, 10?mg/kg | | Administration: | Subcutaneous; daily for 5 days | | Result: | Produced tumor growth inhibition. |
|
|
| Company Name: |
Fuan Bio Gold
|
| Telephone: |
15002819872 |
| Website: |
fuanbio.com |
|